Patients with high dysadherin expression and YAP activation may benefit the most from dysadherin-targeted therapy, and combining dysadherin inhibition with TKIs or immune checkpoint inhibitors could resensitize refractory tumors and address a major clinical challenge in advanced HCC. Here, FXYD5 is linked to hepatocellular carcinoma.